JP2013528650A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528650A5
JP2013528650A5 JP2013515459A JP2013515459A JP2013528650A5 JP 2013528650 A5 JP2013528650 A5 JP 2013528650A5 JP 2013515459 A JP2013515459 A JP 2013515459A JP 2013515459 A JP2013515459 A JP 2013515459A JP 2013528650 A5 JP2013528650 A5 JP 2013528650A5
Authority
JP
Japan
Prior art keywords
ylthio
bromo
triazol
acetic acid
cyclopropylnaphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013515459A
Other languages
English (en)
Japanese (ja)
Other versions
JP5964821B2 (ja
JP2013528650A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/040398 external-priority patent/WO2011159732A1/en
Publication of JP2013528650A publication Critical patent/JP2013528650A/ja
Publication of JP2013528650A5 publication Critical patent/JP2013528650A5/ja
Application granted granted Critical
Publication of JP5964821B2 publication Critical patent/JP5964821B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013515459A 2010-06-15 2011-06-14 痛風と高尿酸血症の処置 Expired - Fee Related JP5964821B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US61/355,004 2010-06-15
US41144910P 2010-11-08 2010-11-08
US61/411,449 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US61/430,522 2011-01-06
US201161489420P 2011-05-24 2011-05-24
US61/489,420 2011-05-24
PCT/US2011/040398 WO2011159732A1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Publications (3)

Publication Number Publication Date
JP2013528650A JP2013528650A (ja) 2013-07-11
JP2013528650A5 true JP2013528650A5 (enExample) 2014-06-05
JP5964821B2 JP5964821B2 (ja) 2016-08-03

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515459A Expired - Fee Related JP5964821B2 (ja) 2010-06-15 2011-06-14 痛風と高尿酸血症の処置

Country Status (19)

Country Link
US (3) US9216179B2 (enExample)
EP (1) EP2582683B1 (enExample)
JP (1) JP5964821B2 (enExample)
CA (1) CA2802407C (enExample)
CY (1) CY1120473T1 (enExample)
DK (1) DK2582683T3 (enExample)
ES (1) ES2670700T3 (enExample)
HR (1) HRP20180780T1 (enExample)
HU (1) HUE038265T2 (enExample)
LT (1) LT2582683T (enExample)
NO (1) NO2019008I1 (enExample)
PL (1) PL2582683T3 (enExample)
PT (1) PT2582683T (enExample)
RS (1) RS57275B1 (enExample)
SI (1) SI2582683T1 (enExample)
SM (1) SMT201800266T1 (enExample)
TR (1) TR201806828T4 (enExample)
WO (1) WO2011159732A1 (enExample)
ZA (1) ZA201300055B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794798C (en) 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
RS57275B1 (sr) * 2010-06-15 2018-08-31 Ardea Biosciences Inc Tretman gihta i hiperurikemije
SG11201402016PA (en) 2011-11-03 2014-05-29 Ardea Biosciences Inc 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
AU2016368622B2 (en) * 2015-12-08 2022-09-08 Ardea Biosciences, Inc. Pharmaceutical composition comprising a potent inhibitor of URAT1
CA3060211C (en) 2018-10-26 2025-05-13 The Procter & Gamble Company TOILET PAPER ROLLS
CA3060180A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
CA3060185A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
CA3060193C (en) 2018-10-26 2023-05-09 The Procter & Gamble Company Paper towel rolls
US20220288038A1 (en) * 2019-08-21 2022-09-15 The University Of Tokyo Abcc11 inhibitor
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE537181T1 (de) 2003-12-26 2011-12-15 Kissei Pharmaceutical Benzimidazolderivate und deren medizinische verwendungen
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
ATE528001T1 (de) 2004-08-25 2011-10-15 Ardea Biosciences Inc S-triazolyl-alpha-mercaptoacetanilide als inhibitoren von hiv-umkehrtranskriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
MX2009007680A (es) 2007-01-19 2011-08-03 Takeda Pharmaceuticals North America Inc Metodos para prevenir o reducir el numero de expansiones graduales de gota utilizando inhibidores de oxidoreductasa de xantina y agentes anti-inflamatorios.
CN103058944B (zh) 2007-11-27 2015-08-05 亚德生化公司 调节血液尿酸水平的化合物
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
KR101294872B1 (ko) 2008-09-04 2013-08-08 아디아 바이오사이언스즈 인크. 요산 수치를 조절하기 위한 화합물, 조성물 및 이들의 사용 방법
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2432774A4 (en) * 2009-05-20 2013-01-02 Ardea Biosciences Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID RATES
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
PH12012501391A1 (en) 2010-01-08 2012-10-29 Ardea Biosciences Inc Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
CA2794798C (en) * 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
RS57275B1 (sr) * 2010-06-15 2018-08-31 Ardea Biosciences Inc Tretman gihta i hiperurikemije
WO2012000103A1 (en) * 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
CA2813555C (en) 2010-10-15 2014-11-25 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
EP2658846B1 (en) 2010-12-30 2016-12-14 Ardea Biosciences, Inc. Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof
CA2837080C (en) 2011-05-24 2017-01-24 Ardea Biosciences, Inc. Hypertension and hyperuricemia

Similar Documents

Publication Publication Date Title
JP2013528650A5 (enExample)
JP2013528655A5 (enExample)
Grassi et al. Clinical features of gout
JP5964821B2 (ja) 痛風と高尿酸血症の処置
JP2014532726A5 (enExample)
JP6120985B2 (ja) ホスホジエステラーゼタイプ5活性阻害剤を含む神経細胞のアポトーシス抑制用組成物
JP2009533356A5 (enExample)
JP2014532647A5 (enExample)
Pascual et al. Febuxostat
JP5649585B2 (ja) ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物
JP2019524897A5 (enExample)
Feng et al. Taurine decreased uric acid levels in hyperuricemic rats and alleviated kidney injury
JP2013087119A5 (enExample)
Müller et al. Aliskiren—mode of action and preclinical data
CN101500561A (zh) 应用铁螯合剂治疗内分泌功能障碍
AU2013212865A1 (en) Therapeutic agent for diabetes
RU2014115733A (ru) Новая соль и медицинское применение
JP2018536638A5 (enExample)
JP2014532758A (ja) ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN101618036A (zh) 羧胺三唑及其可用盐的医药新用途
JP2014532759A5 (enExample)
ul Haq et al. Association of serum uric acid with blood urea and serum creatinine
JP2015512948A (ja) ハロフェナートまたはハロフェン酸および抗炎症剤を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN118178378A (zh) 10-羟基-2-癸烯酸在防治高尿酸血症中的用途
CN102365269A (zh) 用于治疗认知缺损的新药物